Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin's lymphoma in Hokkaido

Annals of Hematology

Volumn 88, Issue 4, 2009, Pages 375-377

  Tsutsumi, Yutaka ^a   Shigematsu, Akio ^b   Hashino, Satoshi ^b   Tanaka, Junji ^b   Chiba, Kouji ^c   Masauzi, Nobuo ^a   Kobayashi, Hajime ^d   Kurosawa, Mitsutoshi ^e   Iwasaki, Hiroshi ^f   Morioka, Masanobu ^g   Asaka, Masahiro ^b   Imamura, Masahiro ^b  

^a Hakodate Municipal Hospital   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Department of Internal Medicine   (Japan)

^d Obihiro Kosei Hospital   (Japan)

^e NATIONAL CANCER CENTER   (Japan)

^f Sapporo Kosei General Hospital   (Japan)

^g JAPANESE RED CROSS SOCIETY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; RITUXIMAB; STEROID;

ANTIBIOTIC PROPHYLAXIS; ANTIBODY TITER; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; HEPATITIS B; HUMAN; JAPAN; LETTER; MAJOR CLINICAL STUDY; MONOTHERAPY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; TREATMENT RESPONSE; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DATA INTERPRETATION, STATISTICAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LYMPHOMA, B-CELL; QUESTIONNAIRES; RETROSPECTIVE STUDIES; VIRUS ACTIVATION;

EID: 60749112817     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0585-6     Document Type: Letter

References (13)

1. Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y et al (2002) Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: A Japanese phase II study. Ann Oncol 13:928-943 doi: 10.1093/annonc/mdf155
2. Bermudez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A (2000) Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 85:894-895
3. Sharma VR, Fleming DR, Slone S (2000) Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 96:1184-1186
4. Suzan F, Ammor M, Ribrag V (2001) Fatal reactivation of cytomegalovirus infection after use of rituximab for a post transplantation lymphoproliferative disorder. N Engl J Med 345:1000 doi: 10.1056/ NEJM200109273451315
5. Goldberg SL, Pecora AL, Alter RS, Kroll MS, Rowley SD, Waintraub SE et al (2002) Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 99:1486-1488 doi: 10.1182/ blood.V99.4.1486
6. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, Lobuglio AF, Jonas C, Kippenstein D, Dallire B, Varns C (1999) Treatment of patients with low grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276
7. Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W et al (2003) Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 102:1930 doi: 10.1182/ blood-2003-05-1403
8. Ng HJ, Lim LC (2001) Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: Case report. Ann Hematol 80:549-552 doi: 10.1007/s002770100346
9. Dervite I, Hober D, Morel P (2001) Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344:68-69 doi: 10.1056/NEJM200101043440120
10. Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Hiroe K, Obara S et al (2004) Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 83:58-60 doi: 10.1007/s00277-003-0748-4
11. Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M et al (2005) Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 4:599-608 doi: 10.1517/14740338.4.3.599
12. Pereau G, Dris N, Estines O, Derancourt C, Levy S, Bernard P (2006) Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 155:1053-1056 doi: 10.1111/j.1365-2133.2006.07451.x
13. Yang SH, Kuo SH (2008) Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma. Ann Hematol 87:325-327 doi: 10.1007/s00277-007-0396-1